Astellas Pharma Global Development, Inc.
Works in Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Astellas Pharma Global Development, Inc. is a clinical trial sponsor. It has 38 active clinical trials with 11,898 planned participants, across 15 therapeutic areas. Since 2021 it has completed 94 trials and stopped 24 early.
Trial track record · since 2021
Pipeline · 38 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Astellas Pharma Global Development, Inc
Astellas Pharma Global Development, Inc is lead sponsor of 38 active clinical trials on ClinicalTrials.gov, with 11,898 planned participants, in Dermatology, Genetic & rare, GI & liver, Hematology and other areas. Since 2021 it has completed 94 trials and stopped 24 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Astellas Pharma Global Development, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Astellas Pharma Global Development, Inc.. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.